![PDF) Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb) PDF) Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)](https://i1.rgstatic.net/publication/371779026_Real-world_outcomes_among_patients_with_metastatic_colorectal_cancer_treated_first_line_with_a_bevacizumab_biosimilar_bevacizumab-awwb/links/64948b52c41fb852dd27072b/largepreview.png)
PDF) Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
These highlights do not include all the information needed to use MVASI safely and effectively. See full prescribing information
![These highlights do not include all the information needed to use MVASI safely and effectively. See full prescribing information for MVASI. MVASI® (bevacizumab-awwb) injection, for intravenous use Initial U.S. Approval: 2017 MVASI ( These highlights do not include all the information needed to use MVASI safely and effectively. See full prescribing information for MVASI. MVASI® (bevacizumab-awwb) injection, for intravenous use Initial U.S. Approval: 2017 MVASI (](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=mvasi-08.jpg&id=700280)
These highlights do not include all the information needed to use MVASI safely and effectively. See full prescribing information for MVASI. MVASI® (bevacizumab-awwb) injection, for intravenous use Initial U.S. Approval: 2017 MVASI (
![PDF) Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb) PDF) Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)](https://www.researchgate.net/publication/371779026/figure/tbl3/AS:11431281169832398@1687456599933/Treatment-regimens-and-effectiveness-among-patients-with-mCRC-treated-with-1L_Q320.jpg)